📰 Nasdaq Edit News
Page 4 - Nasdaq Edit News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Edit. Real-time updates on events, politics, business and more.
August 5, 2023
Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $4.17 million. Editas Medicine had […]
August 5, 2023
Editas Medicine (NASDAQ:EDIT – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The firm had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative net […]
August 3, 2023
Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.20, Briefing.com reports. Editas Medicine had a negative net margin of 960.70% and a negative return on equity of 56.20%. The business had revenue of $2.89 million […]
June 9, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) CEO Gilmore Neil O’neill sold 6,486 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $9.50, for a total value of $61,617.00. Following the sale, the chief executive officer now directly owns 130,169 shares in […]
June 8, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus rating of “Hold” by the fifteen research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The […]
June 8, 2023
Silicon Hills Wealth Management LLC acquired a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 10,000 shares of the company’s stock, valued at approximately $89,000. Other large investors also recently made changes […]
June 7, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) CEO Gilmore Neil O’neill sold 6,486 shares of Editas Medicine stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $9.50, for a total transaction of $61,617.00. Following the completion of the transaction, the chief executive officer now owns […]
June 6, 2023
Shelton Capital Management decreased its holdings in Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) by 7.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,200 shares of the company’s stock after selling 10,200 shares during the quarter. Shelton Capital Management owned about 0.20% of […]
June 6, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) rose 7.4% on Tuesday . The company traded as high as $10.29 and last traded at $10.14. Approximately 564,583 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 1,815,854 shares. The stock had previously closed at $9.44. Wall Street Analysts Forecast […]
June 1, 2023
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 20,230,000 shares, an increase of 7.3% from the April 30th total of 18,860,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is […]